Fermenta Biotech Limited (BOM:506414)
458.25
+8.85 (1.97%)
At close: Aug 17, 2026
Fermenta Biotech Revenue
Fermenta Biotech had revenue of 1.22B INR in the quarter ending June 30, 2026, a decrease of -10.60%. This brings the company's revenue in the last twelve months to 5.11B, down -3.15% year-over-year. In the fiscal year ending March 31, 2026, Fermenta Biotech had annual revenue of 5.25B with 11.92% growth.
Revenue (ttm)
5.11B
Revenue Growth
-3.15%
P/S Ratio
2.57
Revenue / Employee
8.11M
Employees
630
Market Cap
13.14B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 5.25B | 559.52M | 11.92% |
| Mar 31, 2025 | 4.69B | 1.34B | 39.87% |
| Mar 31, 2024 | 3.36B | -142.79M | -4.08% |
| Mar 31, 2023 | 3.50B | -485.75M | -12.19% |
| Mar 31, 2022 | 3.99B | 212.27M | 5.63% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| TTK Healthcare | 8.88B |
| Anuh Pharma | 7.79B |
| Sudarshan Pharma Industries | 7.32B |
| Lincoln Pharmaceuticals | 7.03B |
| Kopran | 7.00B |
| Wanbury | 6.53B |
| Amrutanjan Health Care | 5.11B |
| Syncom Formulations (India) | 4.89B |